Therapeutic Area Expertise

Committed to advancing innovative therapies that make a meaningful difference in patients' lives.

From industry-firsts to well-researched indications, MMS brings a wealth of specialized knowledge across therapeutic areas to ensure that your drug development programs are supported by a team that truly understands the unique challenges and opportunities presented. We are proficient in a diverse range of therapeutic areas, including rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others. Our deep understanding of these complex indications, combined with our data-driven approach and cutting-edge technology, allows us to be your trusted partner.

Whether you are pioneering new treatments for rare diseases, exploring the potential of psychedelics, or developing groundbreaking oncology therapies, MMS can bring your program to life through comprehensive solutions that focus on the long-term health of your project.

Review our therapeutic area expertise to understand how MMS can help you achieve your development goals across a variety of indications.

In addition to the pivotal therapeutic areas above, MMS global colleagues possess a depth and breadth of industry expertise that is unmatched in other areas.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization